1. Home
  2. SCLX vs SYTA Comparison

SCLX vs SYTA Comparison

Compare SCLX & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • SYTA
  • Stock Information
  • Founded
  • SCLX 2011
  • SYTA N/A
  • Country
  • SCLX United States
  • SYTA Canada
  • Employees
  • SCLX N/A
  • SYTA N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • SYTA Telecommunications Equipment
  • Sector
  • SCLX Health Care
  • SYTA Telecommunications
  • Exchange
  • SCLX Nasdaq
  • SYTA Nasdaq
  • Market Cap
  • SCLX 35.7M
  • SYTA 29.0M
  • IPO Year
  • SCLX N/A
  • SYTA 2020
  • Fundamental
  • Price
  • SCLX $18.73
  • SYTA $3.07
  • Analyst Decision
  • SCLX Strong Buy
  • SYTA
  • Analyst Count
  • SCLX 3
  • SYTA 0
  • Target Price
  • SCLX $367.50
  • SYTA N/A
  • AVG Volume (30 Days)
  • SCLX 309.9K
  • SYTA 1.9M
  • Earning Date
  • SCLX 08-13-2025
  • SYTA 11-13-2025
  • Dividend Yield
  • SCLX N/A
  • SYTA N/A
  • EPS Growth
  • SCLX N/A
  • SYTA N/A
  • EPS
  • SCLX N/A
  • SYTA N/A
  • Revenue
  • SCLX $44,236,000.00
  • SYTA N/A
  • Revenue This Year
  • SCLX $89.26
  • SYTA $1.74
  • Revenue Next Year
  • SCLX $203.95
  • SYTA $16.38
  • P/E Ratio
  • SCLX N/A
  • SYTA N/A
  • Revenue Growth
  • SCLX N/A
  • SYTA 49.13
  • 52 Week Low
  • SCLX $3.60
  • SYTA $0.93
  • 52 Week High
  • SCLX $39.90
  • SYTA $29.20
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 46.04
  • SYTA 59.84
  • Support Level
  • SCLX $14.80
  • SYTA $2.23
  • Resistance Level
  • SCLX $30.90
  • SYTA $3.92
  • Average True Range (ATR)
  • SCLX 3.47
  • SYTA 0.28
  • MACD
  • SCLX -1.47
  • SYTA 0.10
  • Stochastic Oscillator
  • SCLX 23.68
  • SYTA 50.00

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About SYTA Siyata Mobile Inc.

Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.

Share on Social Networks: